The US Food and Drug Administration authorized Novo Nordisk’s weight-loss capsule on Monday, giving the Danish drugmaker a leg up within the race to market a potent oral remedy for shedding kilos because it seems to be to regain misplaced floor from rival Eli Lilly.
The capsule is 25 milligrams of semaglutide, the identical lively ingredient in injectable Wegovy and Ozempic, and might be offered beneath the model identify Wegovy. Novo already sells an oral semaglutide for sort 2 diabetes, Rybelsus.
The approval may assist spur a turnaround for Novo after a rocky yr of sliding shares, revenue warnings and slowing gross sales of its injectable Wegovy amid intense competitors from Lilly and stress from compounded variations.
A 64-week, late-stage research confirmed individuals who took 25 mg of oral semaglutide as soon as every day misplaced a mean of 16.6 % of their physique weight, in contrast with 2.7 % for these on a placebo.
The capsule was authorized for persistent weight administration in adults with weight problems or obese and at the very least one associated well being situation, broadening the potential affected person pool at a time when insurers, employers and governments are wrestling with spiralling healthcare prices associated to weight problems.
It may assist open the door to tens of tens of millions of untapped sufferers in a world market, forecast to be value some $150 billion a yr by subsequent decade.
By Maggie Fick
Learn extra:
The GLP-1 Arms Race, Explained
The pharmaceutical growth in weight-loss medication has put firms like Novo Nordisk and Eli Lilly in ever-fiercer competitors. Now extra heavyweights, like Pfizer and Astrazeneca, are coming into the ring. Who will come out on prime?